Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2009, Article ID 818065, 12 pages
http://dx.doi.org/10.1155/2009/818065
Review Article

Modalities for Imaging of Prostate Cancer

Division of Urology, University of Colorado Health Sciences Center, UCDSOM, MS C-319, Academic Office One Bldg., 12631 East 17th Ave., Room L15-5602, Aurora, CO 80045, USA

Received 10 June 2009; Revised 8 September 2009; Accepted 31 December 2009

Academic Editor: Maxwell V. Meng

Copyright © 2009 A. H. Hou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, and M. J. Thun, “Cancer statistics, 2007,” CA: A Cancer Journal for Clinicians, vol. 57, no. 1, pp. 43–66, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. E. D. Crawford and A. B. Barqawi, “Targeted focal therapy: a minimally invasive ablation technique for early prostate cancer,” Oncology, vol. 21, no. 1, pp. 27–32, 2007. View at Google Scholar · View at Scopus
  3. M. R. Cooperberg, J. W. Moul, and P. R. Carroll, “The changing face of prostate cancer,” Journal of Clinical Oncology, vol. 23, no. 32, pp. 8146–8151, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  4. V. Scattoni, A. Zlotta, R. Montironi, C. Schulman, P. Rigatti, and F. Montorsi, “Extended and saturation prostatic biopsy in the diagnosis and characterization of prostate cancer: a critical analysis of the literature,” European Urology, vol. 52, pp. 1309–1322, 2007. View at Google Scholar
  5. R. Etzioni, D. F. Penson, J. M. Legler et al., “Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends,” Journal of the National Cancer Institute, vol. 94, no. 13, pp. 981–990, 2002. View at Google Scholar · View at Scopus
  6. G. L. Andriole, R. L. Grubb, S. S. Buys et al., “Mortality results from a randomized prostate-cancer screening trial,” The New England Journal of Medicine, vol. 360, no. 13, pp. 1310–1319, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  7. M. K. Terris and T. A. Stamey, “Determination of prostate volume by transrectal ultrasound,” Journal of Urology, vol. 145, no. 5, pp. 984–987, 1991. View at Google Scholar
  8. K. Shinohara, T. M. Wheeler, and P. T. Scardino, “The appearance of prostate cancer on transrectal ultrasonography: correlation of imagining and pathological examinations,” Journal of Urology, vol. 142, no. 1, pp. 76–82, 1989. View at Google Scholar · View at Scopus
  9. W. J. Ellis, M. P. Chetner, S. D. Preston, and M. K. Brawer, “Diagnosis of prostatic carcinoma: the yield of serum prostate specific antigen, digital rectal examination and transrectal ultrasonography,” Journal of Urology, vol. 152, no. 5, pp. 1520–1525, 1994. View at Google Scholar
  10. H. B. Carter, U. M. Hamper, S. Sheth et al., “Evaluation of transrectal ultrasound in the diagnosis of prostate cancer,” The Journal of Urology, vol. 142, p. 1008, 1989. View at Google Scholar
  11. F. Lee, J. M. Gray, and R. D. McLeary, “Transrectal ultrasound in the diagnosis of prostate cancer: location, echogenicity, histopathology, and staging,” Prostate, vol. 7, no. 2, pp. 117–129, 1985. View at Google Scholar · View at Scopus
  12. E. Kuligowska, M. A. Barish, H. M. Fenlon, and M. Blake, “Predictors of prostate carcinoma: accuracy of gray-scale and color Doppler US and serum markers,” Radiology, vol. 220, no. 3, pp. 757–764, 2001. View at Google Scholar · View at Scopus
  13. H. Hricak, P. L. Choyke, S. C. Eberhardt, S. A. Leibel, and P. T. Scardino, “Imaging prostate cancer: a multidisciplinary perspective,” Radiology, vol. 243, no. 1, pp. 28–53, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  14. O. Ukimura, P. Troncoso, E. I. Ramirez, and R. J. Babaian, “Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension,” Journal of Urology, vol. 159, no. 4, pp. 1251–1259, 1998. View at Publisher · View at Google Scholar · View at Scopus
  15. J. A. Smith Jr., P. T. Scardino, M. I. Resnick, A. D. Hernandez, S. C. Rose, and M. J. Egger, “Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective, multi-institutional trial,” Journal of Urology, vol. 157, no. 3, pp. 902–906, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Ohori, S. Egawa, K. Shinohara, T. M. Wheeler, and P. T. Scardino, “Detection of microscopic extracapsular extension prior to radical prostatectomy for clinically localized prostate cancer,” British Journal of Urology, vol. 74, no. 1, pp. 72–79, 1994. View at Google Scholar · View at Scopus
  17. H. Augustin, M. Graefen, J. Palisaar et al., “Prognostic significance of visible lesions on transrectal ultrasound in impalpable prostate cancers: implications for staging,” Journal of Clinical Oncology, vol. 21, no. 15, pp. 2860–2868, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. M. Ohori, M. W. Kattan, T. Utsunomiya, K. Suyama, P. T. Scardino, and T. M. Wheeler, “Do impalpable stage T1c prostate cancers visible on ultrasound differ from those not visible?” Journal of Urology, vol. 169, no. 3, pp. 964–968, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. M. L. Eisenberg, J. E. Cowan, B. J. Davies, P. R. Carroll, and K. Shinohara, “The importance of tumor palpability and transrectal ultrasonographic appearance in the contemporary clinical staging of prostate cancer,” Urologic Oncology. In press. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  20. R. J. A. Van Moorselaar and E. E. Voest, “Angiogenesis in prostate cancer: its role in disease progression and possible therapeutic approaches,” Molecular and Cellular Endocrinology, vol. 197, no. 1-2, pp. 239–250, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Wink, F. Frauscher, D. Cosgrove et al., “Contrast-enhanced ultrasound and prostate cancer; a multicentre European research coordination project,” European Urology, vol. 54, no. 5, pp. 982–993, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  22. D. Strohmeyer, F. Frauscher, A. Klauser et al., “Contrast-enhanced transrectal color Doppler ultrasonography (TRCDUS) for assessment of angiogenesis in prostate cancer,” Anticancer Research, vol. 21, no. 4, pp. 2907–2913, 2001. View at Google Scholar · View at Scopus
  23. E. J. Halpern, L. Verkh, F. Forsberg, L. G. Gomella, R. F. Mattrey, and B. B. Goldberg, “Initial experience with contrast-enhanced sonography of the prostate,” American Journal of Roentgenology, vol. 174, no. 6, pp. 1575–1580, 2000. View at Google Scholar · View at Scopus
  24. M. Mitterberger, W. Horninger, A. Pelzer et al., “A prospective randomized trial comparing contrast-enhanced targeted versus systematic ultrasound guided biopsies: impact on prostate cancer detection,” Prostate, vol. 67, no. 14, pp. 1537–1542, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  25. J. P. M. Sedelaar, G. J. L. H. van Leedners et al., “Value of contrast US in the detection of significant prostate cancer: correlation with radical prostatectomy specimens,” Prostate, vol. 53, pp. 246–253, 2002. View at Google Scholar
  26. L. Pallwein, M. Mitterberger, P. Struve et al., “Real-time elastography for detecting prostate cancer: preliminary experience,” BJU International, vol. 100, no. 1, pp. 42–46, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  27. E. D. Nelson, C. B. Slotoroff, L. G. Gomella, and E. J. Halpern, “Targeted biopsy of the prostate: the impact of color doppler imaging and elastography on prostate cancer detection and Gleason score,” Urology, vol. 70, no. 6, pp. 1136–1140, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  28. G. Salomon, J. Kollerman, I. Thederan et al., “Evaluation of CaP detection with US real-time elastography: a comparison with step section pathological analysis after radical prostatectomy,” European Urology, vol. 54, no. 6, pp. 1354–1362, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  29. K. Kamoi, K. Okihara, A. Ochiai et al., “The utility of transrectal real-time elastography in the diagnosis of prostate cancer,” Ultrasound in Medicine and Biology, vol. 34, no. 7, pp. 1025–1032, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  30. J. Braeckman, P. Autier, C. Garbar et al., “Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer,” BJU International, vol. 101, no. 3, pp. 293–298, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  31. D. Beyersdorff, M. Taupitz, B. Winkelmann et al., “Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging,” Radiology, vol. 224, no. 3, pp. 701–706, 2002. View at Google Scholar · View at Scopus
  32. J. C. Presti Jr., H. Hricak, P. A. Narayan, K. Shinohara, S. White, and P. R. Carroll, “Local staging of prostatic carcinoma: comparison of transrectal sonography and endorectal MR imaging,” American Journal of Roentgenology, vol. 166, no. 1, pp. 103–108, 1996. View at Google Scholar · View at Scopus
  33. M. Mullerad, H. Hricak, K. Kuroiwa et al., “Comparison of endorectal magnetic resonance imaging, guided prostate biopsy and digital rectal examination in the preoperative anatomical localization of prostate cancer,” Journal of Urology, vol. 174, no. 6, pp. 2158–2163, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  34. A. P. S. Kirkham, M. Emberton, and C. Allen, “How good is MRI at detecting and characterising cancer within the prostate?” European Urology, vol. 50, no. 6, pp. 1163–1175, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  35. A. E. Wefer, H. Hricak, D. B. Vigneron et al., “Sextant localization of prostate cancer: comparison of sextant biopsy, magnetic resonance imaging and magnetic resonance spectroscopic imaging with step section histology,” Journal of Urology, vol. 164, no. 2, pp. 400–404, 2000. View at Google Scholar · View at Scopus
  36. S. White, H. Hricak, R. Forstner et al., “Prostate cancer: effect of postbiopsy hemorrhage on interpretation of MR images,” Radiology, vol. 195, no. 2, pp. 385–390, 1995. View at Google Scholar · View at Scopus
  37. S. Ikonen, L. Kivisaari, T. Vehmas et al., “Optimal timing of post-biopsy MR imaging of the prostate,” Acta Radiologica, vol. 42, no. 1, pp. 70–73, 2001. View at Google Scholar · View at Scopus
  38. A. Qayyum, F. V. Coakley, Y. Lu et al., “Organ-confined prostate cancer: effect of prior transrectal biopsy on endorectal MRI and MR spectroscopic imaging,” American Journal of Roentgenology, vol. 183, no. 4, pp. 1079–1083, 2004. View at Google Scholar · View at Scopus
  39. J. H. Ellis, C. Tempany, M. S. Sarin, C. Gatsonis, M. D. Rifkin, and B. J. McNeil, “MR imaging and sonography of early prostatic cancer: pathologic and imaging features that influence identification and diagnosis,” American Journal of Roentgenology, vol. 162, no. 4, pp. 865–872, 1994. View at Google Scholar · View at Scopus
  40. O. Akin, E. Sala, C. S. Moskowitz et al., “Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging,” Radiology, vol. 239, no. 3, pp. 784–792, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  41. J. Comet-Batlle, J. C. Vilanova-Busquets, J. M. Saladié-Roig, A. Gelabert-Mas, C. Barceló-Vidal, and J. A. Spencer, “The value of endorectal MRI in the early diagnosis of prostate cancer,” European Urology, vol. 44, no. 2, pp. 201–208, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. B. Djavan, V. Ravery, A. Zlotta et al., “Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop?” Journal of Urology, vol. 166, pp. 1679–1683, 2001. View at Google Scholar
  43. A. B. Cheikh, N. Girouin, M. Colombel et al., “Evaluation of T2-weighted and dynamic contrast-enhanced MRI in localizing prostate cancer before repeat biopsy,” European Radiology, vol. 19, no. 3, pp. 770–778, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  44. D. Beyersdorff, A. Winkel, B. Hamm, S. Lenk, S. A. Loening, and M. Taupitz, “MR imaging-guided prostate biopsy with a closed MR unit at 1.5 T: initial results,” Radiology, vol. 234, no. 2, pp. 576–581, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  45. K. M. Pondman, J. J. Fütterer, B. ten Haken et al., “MR-guided biopsy of the prostate: an overview of techniques and a systematic review,” European Urology, vol. 54, no. 3, pp. 517–527, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  46. H. Hricak, L. Wang, D. C. Wei et al., “The role of preoperative endorectal magnetic resonance imaging in the decision regarding whether to preserve or resect neurovascular bundles during radical retropubic prostatectomy,” Cancer, vol. 100, no. 12, pp. 2655–2663, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  47. A. P. Labanaris, V. Zugor, S. Takriti et al., “The role of conventional and functional endorectal magnetic resonance imaging in the decision of whether to preserve or resect the neurovascular bundles during radical retropubic prostatectomy,” Scandinavian Journal of Urology and Nephrology, vol. 43, no. 1, pp. 25–31, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  48. F. V. Coakley, S. Eberhardt, D. C. Wei et al., “Blood loss during radical retropubic prostatectomy: relationship to morphologic features on preoperative endorectal magnetic resonance imaging,” Urology, vol. 59, no. 6, pp. 884–888, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. K. K. Yu, J. Scheidler, H. Hricak et al., “Prostate cancer: prediction of extracapsular extension with endorectal MR imaging and three-dimensional proton MR spectroscopic imaging,” Radiology, vol. 213, no. 2, pp. 481–488, 1999. View at Google Scholar · View at Scopus
  50. G. J. Jager, E. T. G. Ruijter et al., “Local staging of prostate cancer with endorectal MRI: correlation with histopathology,” American Journal of Roentgenology, vol. 166, pp. 845–852, 1996. View at Google Scholar
  51. C. K. Kim, B. K. Park, and B. Kim, “Localization of prostate cancer using 3T MRI. Comparison of T2-weighted and dynamic contrast-enhanced imaging,” Journal of Computer Assisted Tomography, vol. 30, no. 1, pp. 7–11, 2006. View at Publisher · View at Google Scholar · View at Scopus
  52. A. O. Sartor, H. Hricak et al., “Evaluating localized Pca and identifying candidates for focal therapy,” The Journal of Urology, vol. 72, supplement 6A, pp. 12–24, 2008. View at Google Scholar
  53. J. J. Fütterer, J. O. Barentsz, and S. W. Heijmink, “Value of 3-T magnetic resonance imaging in local staging of prostate cancer,” Topics in Magnetic Resonance Imaging, vol. 19, no. 6, pp. 285–289, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  54. M. Mullerad, H. Hricak, L. Wang et al., “PCa: detection of extracapsular extension by GU and general body radiologists at MR imaging,” Radiology, vol. 232, pp. 133–139, 2004. View at Google Scholar
  55. C. M. Tempany, X. Zhou, E. A. Zerhouni et al., “Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques,” Radiology, vol. 192, no. 1, pp. 47–54, 1994. View at Google Scholar
  56. M. D. Rifkin, E. A. Zerhouni, C. A. Gatsonis et al., “Comparison of magnetic resonance imaging and ultrasonography in staging early prostate cancer. Results of a multi-institutional cooperative trial,” The New England Journal of Medicine, vol. 323, no. 10, pp. 621–626, 1990. View at Google Scholar
  57. J. S. Wolf Jr., M. Cher, M. Dall'Era, J. C. Presti Jr., H. Hricak, and P. R. Carroll, “The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy,” Journal of Urology, vol. 153, no. 3, pp. 993–999, 1995. View at Publisher · View at Google Scholar · View at Scopus
  58. H. Hricak, S. White, D. Vigneron et al., “Carcinoma of the prostate gland: MR imaging with pelvic phased-array coils versus integrated endorectal-pelvic phased-array coils,” Radiology, vol. 193, no. 3, pp. 703–709, 1994. View at Google Scholar · View at Scopus
  59. L. Wang, M. Mullerad, H.-N. Chen et al., “Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension,” Radiology, vol. 232, no. 1, pp. 133–139, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  60. M. R. Engelbrecht, G. J. Jager, R. J. Laheij, A. L. M. Verbeek, H. J. van Lier, and J. O. Barentsz, “Local staging of prostate cancer using magnetic resonance imaging: a meta-analysis,” European Radiology, vol. 12, no. 9, pp. 2294–2302, 2002. View at Google Scholar · View at Scopus
  61. S. S. Sonnad, C. P. Langlotz, and J. S. Schwartz, “Accuracy of MR imaging for staging prostate cancer: a meta-analysis to examine the effect of technologic change,” Academic Radiology, vol. 8, no. 2, pp. 149–157, 2001. View at Google Scholar · View at Scopus
  62. P. Torricelli, F. Cinquantini, G. Ligabue, G. Bianchi, P. Sighinolfi, and R. Romagnoli, “Comparative evaluation between external phased array coil at 3 T and endorectal coil at 1.5 T: preliminary results,” Journal of Computer Assisted Tomography, vol. 30, no. 3, pp. 355–361, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. J. J. Fütterer, M. R. Engelbrecht, G. J. Jager et al., “Prostate cancer: comparison of local staging accuracy of pelvic phased-array coil alone versus integrated endorectal-pelvic phased-array coils,” European Radiology, vol. 17, no. 4, pp. 1055–1065, 2007. View at Publisher · View at Google Scholar · View at PubMed
  64. A. Graser, A. Heuck, B. Sommer et al., “Per-sextant localization and staging of prostate cancer: correlation of imaging findings with whole-mount step section histopathology,” American Journal of Roentgenology, vol. 188, no. 1, pp. 84–90, 2007. View at Publisher · View at Google Scholar · View at PubMed
  65. S. W. Heijmink, J. J. Fütterer, T. Hambrock et al., “Prostate cancer: body array versus endorectal coil MR imaging at 3T—comparison of image quality, localization, and staging performance,” Radiology, vol. 244, no. 1, pp. 184–195, 2007. View at Publisher · View at Google Scholar · View at PubMed
  66. J. J. Fütterer, S. W. Heijmink, T. W. J. Scheenen et al., “Prostate cancer: local staging at 3-T endorectal MR imaging—early experience,” Radiology, vol. 238, no. 1, pp. 184–191, 2006. View at Publisher · View at Google Scholar · View at PubMed
  67. L. Wang, H. Hricak, M. W. Kattan, H.-N. Chen, P. T. Scardino, and K. Kuroiwa, “Prediction of organ-confined prostate cancer: incremental value of MR imaging and MR spectroscopic imaging to staging nomograms,” Radiology, vol. 238, no. 2, pp. 597–603, 2006. View at Publisher · View at Google Scholar · View at PubMed
  68. M. R. Engelbrecht, G. J. Jager, and J. L. Severens, “Patient selection for magnetic resonance imaging of prostate cancer,” European Urology, vol. 40, no. 3, pp. 300–307, 2001. View at Publisher · View at Google Scholar
  69. F. L. Green, D. L. Page, I. D. Fleming et al., AJCC Cancer Staging Manual, Springer, New York, NY, USA, 2002.
  70. A. V. D'Amico, R. Whittington, B. Malkowicz et al., “Endorectal magnetic resonance imaging as a predictor of biochemical outcome after radical prostatectomy in men with clinically localized prostate cancer,” Journal of Urology, vol. 164, no. 3, pp. 759–763, 2000. View at Google Scholar · View at Scopus
  71. F. May, T. Treumann, P. Dettmar, R. Hartung, and J. Breul, “Limited value of endorectal magnetic resonance imaging and transrectal ultrasonography in the staging of clinically localized prostate cancer,” BJU International, vol. 87, no. 1, pp. 66–69, 2001. View at Publisher · View at Google Scholar · View at Scopus
  72. C. Testa, R. Schiavina, R. Lodi et al., “Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and C11-choline PET/CT,” Radiology, vol. 244, no. 3, pp. 797–806, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  73. J. Scheidler, H. Hricak, D. B. Vigneron et al., “Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging—clinicopathologic study,” Radiology, vol. 213, no. 2, pp. 473–480, 1999. View at Google Scholar · View at Scopus
  74. J. Scheidler, H. Hricak, D. B. Vigneron et al., “Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging—clinicopathologic study,” Radiology, vol. 213, no. 2, pp. 473–480, 1999. View at Google Scholar · View at Scopus
  75. A. Shukla-Dave, H. Hricak, M. W. Kattan et al., “The utility of magnetic resonance imaging and spectroscopy for predicting insignificant prostate cancer: an initial analysis,” BJU International, vol. 99, no. 4, pp. 786–793, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  76. F. V. Coakley, J. Kurhanewicz, Y. Lu et al., “Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging,” Radiology, vol. 223, no. 1, pp. 91–97, 2002. View at Google Scholar · View at Scopus
  77. J. C. Weinreb, J. D. Blume, F. V. Coakley et al., “Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy—results of ACRIN prospective multi-institutional clinicopathologic study,” Radiology, vol. 251, no. 1, pp. 122–133, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  78. K. L. Zakian, K. Sircar, H. Hricak et al., “Correlation of proton MR spectroscopic imaging with gleason score based on step-section pathologic analysis after radical prostatectomy,” Radiology, vol. 234, no. 3, pp. 804–814, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  79. D. Pucar, A. Shukla-Dave, H. Hricak et al., “Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy—iInitial experience,” Radiology, vol. 236, no. 2, pp. 545–553, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  80. J. C. Vilanova and J. Barceló, “Prostate cancer detection: magnetic resonance (MR) spectroscopic imaging,” Abdominal Imaging, vol. 32, no. 2, pp. 253–261, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  81. F. Parivar, H. Hricak, K. Shinohara et al., “Detection of locally recurrent prostate cancer after cryosurgery: evaluation by transrectal ultrasound, magnetic resonance imaging, and three- dimensional proton magnetic resonance spectroscopy,” Urology, vol. 48, no. 4, pp. 594–599, 1996. View at Publisher · View at Google Scholar · View at Scopus
  82. R. Alonzi, A. R. Padhani, and C. Allen, “Dynamic contrast enhanced MRI in prostate cancer,” European Journal of Radiology, vol. 63, no. 3, pp. 335–350, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  83. M.-C. Bettencourt, J. J. Bauer, I. A. Sesterhenn, R. R. Connelly, and J. W. Moul, “CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy,” Journal of Urology, vol. 160, no. 2, pp. 459–465, 1998. View at Publisher · View at Google Scholar · View at Scopus
  84. G. Brown, D. A. Macvicar, V. Ayton, and J. E. Husband, “The role of intravenous contrast enhancement in magnetic resonance imaging of prostatic carcinoma,” Clinical Radiology, vol. 50, no. 9, pp. 601–606, 1995. View at Google Scholar · View at Scopus
  85. G. J. Jager, E. T. G. Ruijter, C. A. van de Kaa et al., “Dynamic TurboFLASH subtraction technique for contrast-enhanced MR imaging of the prostate: correlation with histopathologic results,” Radiology, vol. 203, no. 3, pp. 645–652, 1997. View at Google Scholar · View at Scopus
  86. H.-P. Schlemmer, J. Merkle, R. Grobholz et al., “Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens?” European Radiology, vol. 14, no. 2, pp. 309–317, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  87. N. Hara, M. Okuizumi, H. Koike, M. Kawaguchi, and V. Bilim, “Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer,” Prostate, vol. 62, no. 2, pp. 140–147, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  88. S. Muramoto, H. Uematsu, H. Kimura et al., “Differentiation of prostate cancer from benign prostate hypertrophy using dual-echo dynamic contrast MR imaging,” European Journal of Radiology, vol. 44, no. 1, pp. 52–58, 2002. View at Publisher · View at Google Scholar · View at Scopus
  89. H. Ito, K. Kamoi, K. Yokoyama, K. Yamada, and T. Nishimura, “Visualization of prostate cancer using dynamic contrast-enhanced MRI: comparison with transrectal power Doppler ultrasound,” The British Journal of Radiology, vol. 76, no. 909, pp. 617–624, 2003. View at Google Scholar · View at Scopus
  90. B. N. Bloch, E. Furman-Haran, T. H. Helbich et al., “Prostate cancer: accurate determination of extracapsular extension with high-spatial-resolution dynamic contrast-enhanced and T2-weighted MR imaging—initial results,” Radiology, vol. 245, no. 1, pp. 176–185, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  91. K. Ogura, S. Maekawa, K. Okubo et al., “Dynamic endorectal magnetic resonance imaging for local staging and detection of neurovascular bundle involvement of prostate cancer: correlation with histopathologic results,” Urology, vol. 57, no. 4, pp. 721–726, 2001. View at Google Scholar · View at Scopus
  92. J. J. Fütterer, S. W. Heijmink, T. W. J. Scheenen et al., “Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging,” Radiology, vol. 241, no. 2, pp. 449–458, 2006. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  93. T. Namimoto, S. Morishita, R. Saitoh, J. Kudoh, Y. Yamashita, and M. Takahashi, “The value of dynamic MR imaging for hypointensity lesions of the peripheral zone of the prostate,” Computerized Medical Imaging and Graphics, vol. 22, no. 3, pp. 239–245, 1998. View at Publisher · View at Google Scholar · View at Scopus
  94. J. H. Mydlo, J. G. Kral, M. Volpe, C. Axotis, R. J. Macchia, and L. P. Pertschuk, “An analysis of microvessel density, androgen receptor, p53 and HER-2/neu expression and Gleason score in prostate cancer. Preliminary results and therapeutic implications,” European Urology, vol. 34, no. 5, pp. 426–432, 1998. View at Publisher · View at Google Scholar · View at Scopus
  95. A. A. Sinha, B. J. Quast, P. K. Reddy et al., “Microvessel density as a molecular marker for identifying high-grade prostatic intraepithelial neoplasia precursors to prostate cancer,” Experimental and Molecular Pathology, vol. 77, no. 2, pp. 153–159, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  96. A. R. Padhani, C. J. Gapinski, D. A. Macvicar et al., “Dynamic contrast enhanced MRI of prostate cancer: correlation with morphology and tumour stage, histological grade and PSA,” Clinical Radiology, vol. 55, no. 2, pp. 99–109, 2000. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  97. C. K. Kim and B. K. Park, “Update of prostate MRI at 3T,” Journal of Computer Assisted Tomography, vol. 32, no. 2, pp. 163–172, 2008. View at Google Scholar
  98. J. J. Fütterer, T. W. J. Scheenen, H. J. Huisman et al., “Initial experience of 3 tesla endorectal coil magnetic resonance imaging and 1H-spectroscopic imaging of the prostate,” Investigative Radiology, vol. 39, no. 11, pp. 671–680, 2004. View at Publisher · View at Google Scholar · View at Scopus
  99. L. W. Turnbull, D. L. Buckley, L. S. Turnbull, G. P. Liney, and A. J. Knowles, “Differentiation of prostatic carcinoma and benign prostatic hyperplasia: correlation between dynamic Gd-DTPA-enhanced MR imaging and histopathology,” Journal of Magnetic Resonance Imaging, vol. 9, no. 2, pp. 311–316, 1999. View at Publisher · View at Google Scholar · View at Scopus
  100. M. A. Jacobs, R. Ouwerkerk, K. Petrowski, and K. J. MacUra, “Diffusion-weighted imaging with apparent diffusion coefficient mapping and spectroscopy in prostate cancer,” Topics in Magnetic Resonance Imaging, vol. 19, no. 6, pp. 261–272, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  101. B. Issa, “In vivo measurement of the apparent diffusion coefficient in normal and malignant prostatic tissues using echo-planar imaging,” Journal of Magnetic Resonance Imaging, vol. 16, no. 2, pp. 196–200, 2002. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  102. C. Sato, S. Naganawa, T. Nakamura et al., “Differentiation of noncancerous tissue and cancer lesion by apparent diffusion coefficient values in transition and peripheral zones of the prostate,” Journal of Magnetic Resonance Imaging, vol. 21, no. 3, pp. 258–262, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  103. Y. Mazaheri, A. Shukla-Dave, H. Hricak et al., “Prostate cancer: identification with combined diffusion-weighted MR imaging and 3D1H MR spectroscopic imaging—correlation with pathologic findings,” Radiology, vol. 246, no. 2, pp. 480–488, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  104. A. Tanimoto, J. Nakashima, H. Kohno, H. Shinmoto, and S. Kuribayashi, “Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging,” Journal of Magnetic Resonance Imaging, vol. 25, no. 1, pp. 146–152, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  105. C. K. Kim, B. K. Park, and H. M. Lee, “Prediction of locally recurrent prostate cancer after radiation therapy: incremental value of 3T diffusion-weighted MRI,” Journal of Magnetic Resonance Imaging, vol. 29, no. 2, pp. 391–397, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  106. Y. Mazaheri, H. Hricak, S. W. Fine et al., “Prostate tumor volume measurement with combined T2-weighted imaging and diffusion-weighted MR: correlation with pathologic tumor volume,” Radiology, vol. 252, no. 2, pp. 449–457, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  107. B. K. Park, H. M. Lee, C. K. Kim, H. Y. Choi, and J. W. Park, “Lesion localization in patients with a previous negative transrectal ultrasound biopsy and persistently elevated prostate specific antigen level using diffusion-weighted imaging at three tesla before rebiopsy,” Investigative Radiology, vol. 43, no. 11, pp. 789–793, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  108. C. K. Kim, B. K. Park, J. J. Han, T. W. Kang, and H. M. Lee, “Diffusion-weighted imaging of the prostate at 3 T for differentiation of malignant and benign tissue in transition and peripheral zones: preliminary results,” Journal of Computer Assisted Tomography, vol. 31, no. 3, pp. 449–454, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  109. J. O. Barentsz, J. J. Fütterer, and S. Takahashi, “Use of ultrasmall superparamagnetic iron oxide in lymph node MR imaging in prostate cancer patients,” European Journal of Radiology, vol. 63, no. 3, pp. 369–372, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  110. M. G. Harisinghani, J. Barentsz, P. F. Hahn et al., “Noninvasive detection of clinically occult lymph-node metastases in prostate cancer,” The New England Journal of Medicine, vol. 348, no. 25, pp. 2491–2499, 2003. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  111. R. W. Ross, A. L. Zietman, W. Xie et al., “Lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) identifies occult lymph node metastases in prostate cancer patients prior to salvage radiation therapy,” Clinical Imaging, vol. 33, no. 4, pp. 301–305, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  112. R. H. Oyen, H. P. van Poppel, F. E. Ameye, W. A. Van De Voorde, A. L. Baert, and L. V. Baert, “Lymph node staging of localized prostatic carcinoma with CT and CT-guided fine-needle aspiration biopsy: prospective study of 285 patients,” Radiology, vol. 190, no. 2, pp. 315–322, 1994. View at Google Scholar
  113. J. W. Walsh, M. A. Amendola et al., “CT detection of pelvic and inguinal LN metastases from primary and recurrent pelvic malignant disease,” Radiology, vol. 137, pp. 157–166, 1980. View at Google Scholar
  114. G. J. O'Dowd, R. W. Veltri, R. Orozco, M. C. Miller, and J. E. Oesterling, “Update on the appropriate staging evaluation for newly diagnosed prostate cancer,” Journal of Urology, vol. 158, no. 3, pp. 687–698, 1997. View at Publisher · View at Google Scholar · View at Scopus
  115. J. W. Walsh, M. A. Amendola, and K. F. Konerding, “Computed tomographic detection of pelvic and inguinal lymph-node metastases from primary and recurrent pelvic malignant disease,” Radiology, vol. 137, no. 1, pp. 157–166, 1980. View at Google Scholar · View at Scopus
  116. J. Rørvik, O. J. Halvorsen, G. Albrektsen, and S. Haukaas, “Lymphangiography combined with biopsy and computer tomography to detect lymph node metastases in localized prostate cancer,” Scandinavian Journal of Urology and Nephrology, vol. 32, no. 2, pp. 116–119, 1998. View at Publisher · View at Google Scholar · View at Scopus
  117. J. S. Wolf Jr., M. Cher, M. Dall'Era, J. C. Presti Jr., H. Hricak, and P. R. Carroll, “The use and accuracy of cross-sectional imaging and fine needle aspiration cytology for detection of pelvic lymph node metastases before radical prostatectomy,” Journal of Urology, vol. 153, no. 3, pp. 993–999, 1995. View at Publisher · View at Google Scholar · View at Scopus
  118. I. J. Liu, M. B. Zafar, Y.-H. Lai, G. M. Segall, and M. K. Terris, “Fluorodeoxyglucose positron emission tomography studies in diagnosis and staging of clinically organ-confined prostate cancer,” Urology, vol. 57, no. 1, pp. 108–111, 2001. View at Publisher · View at Google Scholar · View at Scopus
  119. C. Hofer, C. Laubenbacher, T. Block, J. Breul, R. Hartung, and M. Schwaiger, “Fluorine-18-fluorodeoxyglucose positron emission tomography is useless for the detection of local recurrence after radical prostatectomy,” European Urology, vol. 36, no. 1, pp. 31–35, 1999. View at Publisher · View at Google Scholar · View at Scopus
  120. P. J. Effert, R. Bares, S. Handt, J. M. Wolff, U. Büll, and G. Jakse, “Metabolic imaging of untreated prostate cancer by positron emission tomography with 18fluorine-labeled deoxyglucose,” Journal of Urology, vol. 155, no. 3, pp. 994–998, 1996. View at Google Scholar · View at Scopus
  121. P. D. Shreve, H. B. Grossman, M. D. Gross, and R. L. Wahl, “Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose,” Radiology, vol. 199, no. 3, pp. 751–756, 1996. View at Google Scholar · View at Scopus
  122. J. Sung, J. I. Espiritu, G. M. Segall, and M. K. Terris, “Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer,” BJU International, vol. 92, no. 1, pp. 24–27, 2003. View at Publisher · View at Google Scholar · View at Scopus
  123. N. Oyama, H. Akino, Y. Suzuki et al., “The increased accumulation of [18F]fluorodeoxyglucose in untreated prostate cancer,” Japanese Journal of Clinical Oncology, vol. 29, no. 12, pp. 623–629, 1999. View at Google Scholar · View at Scopus
  124. P. L. Jager, W. Vaalburg, J. Pruim, E. G. E. De Vries, K.-J. Langen, and D. A. Piers, “Radiolabeled amino acids: basic aspects and clinical applications in oncology,” Journal of Nuclear Medicine, vol. 42, no. 3, pp. 432–445, 2001. View at Google Scholar · View at Scopus
  125. D. T. Schmid, H. John, R. Zweifel et al., “Fluorocholine PET/CT in patients with prostate cancer: initial experience,” Radiology, vol. 235, no. 2, pp. 623–628, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  126. I. Igerc, S. Kohlfürst, H. J. Gallowitsch et al., “The value of 18F-Choline PET/CT in patients with elevated PSA-level and negative prostate needle biopsy for localisation of prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 5, pp. 976–983, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  127. R. Schiavina, V. Scattoni, P. Castellucci et al., “C11-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms,” European Urology, vol. 54, no. 2, pp. 392–401, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  128. D. B. Husarik, R. Miralbell, M. Dubs et al., “Evaluation of [18F]-choline PET/CT for staging and restaging of prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 2, pp. 253–263, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  129. K. Bouchelouche, J. Capala, and P. Oehr, “Positron emission tomography/computed tomography and radioimmunotherapy of prostate cancer,” Current Opinion in Oncology, vol. 21, no. 5, pp. 469–474, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  130. L. Rinnab, F. M. Mottaghy, J. Simon et al., “[C11]choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer: preliminary results of a prospective study,” Urologia Internationalis, vol. 81, no. 2, pp. 191–197, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  131. L. Rinnab, J. Simon, R. E. Hautmann et al., “[C11]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy,” World Journal of Urology, vol. 27, no. 5, pp. 619–625, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  132. B. J. Krause, M. Souvatzoglou, M. Tuncel et al., “The detection rate of [C11]choline-PET/CT depends on the serum PSA-value in patients with biochemical recurrence of prostate cancer,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 18–23, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  133. S. N. Reske, N. M. Blumstein, and G. Glatting, “[C11]choline PET/CT imaging in occult local relapse of prostate cancer after radical prostatectomy,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 35, no. 1, pp. 9–17, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  134. R. Nuñez, H. A. Macapinlac, H. W. D. Yeung et al., “Combined 18F-FDG and C11-methionine PET scans in patients with newly progressive metastatic prostate cancer,” Journal of Nuclear Medicine, vol. 43, no. 1, pp. 46–55, 2002. View at Google Scholar · View at Scopus
  135. J. A. Richter, M. Rodríguez, J. Rioja et al., “Dual tracer C11-choline and FDG-PET in the diagnosis of biochemical prostate cancer relapse after radical treatment,” Molecular Imaging and Biology. In press. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  136. U. Elsässer-Beile, G. Reischl, S. Wiehr et al., “PET imaging of prostate cancer xenografts with a highly specific antibody against the prostate-specific membrane antigen,” Journal of Nuclear Medicine, vol. 50, no. 4, pp. 606–611, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  137. R. C. Mease, C. L. Dusich, C. A. Foss et al., “N-[N-[(S)-1,3-dicarboxypropyl]carbamoyl]-4-[18F]fluorobenzyl-L- cysteine, [18F]DCFBC: a new imaging probe for prostate cancer,” Clinical Cancer Research, vol. 14, no. 10, pp. 3036–3043, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  138. “Food and Drug Administration Product Approval Letter: capromab pendetide,” October 1996, http://www.fda.gov/Drugs/DevelopmentApprovalProcess/ HowDrugsareDevelopedandApproved/ApprovalApplications/ TherapeuticBiologicApplications/ucm080734.htm.
  139. D. Kahn, R. D. Williams, M. J. Manyak et al., “111indium-capromab pendetide in the evaluation of patients with residual or recurrent prostate cancer after radical prostatectomy,” Journal of Urology, vol. 159, no. 6, pp. 2041–2047, 1998. View at Google Scholar · View at Scopus
  140. M. A. Seltzer, Z. Barbaric, A. Belldegrun et al., “Comparison of helical computerized tomography, positron emission tomography and monoclonal antibody scans for evaluation of lymph node metastases in patients with prostate specific antigen relapse after treatment for localized prostate cancer,” Journal of Urology, vol. 162, no. 4, pp. 1322–1328, 1999. View at Publisher · View at Google Scholar · View at Scopus
  141. S. N. Nagda, N. Mohideen, S. S. Lo et al., “Long-term follow-up of 111In-capromab pendetide (ProstaScint) scan as pretreatment assessment in patients who undergo salvage radiotherapy for rising prostate-specific antigen after radical prostatectomy for prostate cancer,” International Journal of Radiation Oncology Biology Physics, vol. 67, no. 3, pp. 834–840, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  142. J. K. Troyer, M. L. Beckett, and G. L. Wright Jr., “Location of prostate-specific membrane antigen in the LNCaP prostate carcinoma cell line,” Prostate, vol. 30, no. 4, pp. 232–242, 1997. View at Publisher · View at Google Scholar · View at Scopus
  143. S. S. Chang, V. E. Reuter, W. D. W. Heston, N. H. Bander, L. S. Grauer, and P. B. Gaudin, “Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature,” Cancer Research, vol. 59, no. 13, pp. 3192–3198, 1999. View at Google Scholar · View at Scopus